- Email: [email protected]
Author Biographical Sketch
Joseph A. Roscoe, PhD, is a Research Associate Professor of Radiation Oncology at the University of Rochester, James P. Wilmot Cancer Center, Rochester, New York and has been an active contributor to the Cancer Control Program for nine years. Dr. Roscoe’s degree is in social psychology, and his specialty is the study of symptom relief in patients receiving chemotherapy or radiation therapy with a focus on the role of response expectancies in the development of treatment-related side effects. In addition to his own grants studying the placebo effect and the relationship between abnormalities in sleep architecture and chemotherapy-related fatigue, he is a co-principal investigator on an NCI-supported RT25 Cancer Control Research Training Grant and on the University of Rochester Cancer Center Community Clinical Oncology Program Research Base. Pascal Jean-Pierre, PhD, is a Research Assistant Professor of Radiation Oncology at the University of Rochester, James P. Wilmot Cancer Center. He received his PhD in Clinical Psychology from the University of Rhode Island and completed his pre-doctoral clinical psychology internship at Pilgrim Psychiatric Center, West Brentwood, New York. Dr. Jean-Pierre’s research interests are in symptom management, healthcare disparities, and biostatistics. Presently, he is working on studies that examine the roles of culture and socio-demographics on health beliefs and behavior among diverse populations, as well as studies that examine cognitive and behavioral factors related to side effect development and symptom management. Abhay R. Shelke, MD, is a Research Assistant Professor in the Department of Radiation Oncology at the University of Rochester, James P. Wilmot Cancer Center, Rochester, NewYork. Dr. Shelke graduated from Shri Vasantrao Naik Government Medical College, Yavatmal, India and completed his residency in Physiology at All India Institute of Medical Sciences, New Delhi, India. He is actively involved in investigating the role of autonomic nervous system in development of chemotherapy-induced nausea. His research interests include understanding and managing side effects of chemotherapy and radiotherapy. Maralyn E. Kaufman, PhD, is an Assistant Professor in the Behavioral Medicine Unit in the Department of Radiation Oncology at the University of Rochester, James P. Wilmot Cancer Center, Rochester, New York. Dr. Kaufman earned her MA in Curr Probl Cancer, March/April 2006
37
Pharmacology from Dartmouth Medical School and her PhD in Pharmacology and Toxicology from the University of Louisville. She has conducted independent research and published in the fields of neurobehavioral pharmacology, gastroenterology, and molecular transport. She has also worked as an Associate Editor of the Journal of Pharmaceutical Sciences. Christopher Bole, MA, is a statistician in the Behavioral Medicine Unit in the Department of Radiation Oncology of the University of Rochester, James P. Wilmot Cancer Center. He completed his undergraduate degree in applied mathematics in 1989, and finished a graduate degree in mathematics and statistics in 1991. Subsequently, Mr. Bole held supervisory and senior analyst positions in the federal government and private industry. His work at the Cancer Center began in September of 2004, where he assists in the statistical training of new fellows, contributes original writing and to the editing of manuscripts, and provides computer programming support. Gary R. Morrow, PhD, MS, Professor of Radiation Oncology and Professor of Psychiatry, is the Associate Director for Cancer Control at the University of Rochester, James P. Wilmot Cancer Center, and Director of the URCC CCOP Research Base. He has been engaged in cancer control research at the University of Rochester since 1975, with a primary, sustained focus on side effect management and the methodology of clinical trials in cancer control. Dr. Morrow’s research has received continuous peer-reviewed research funding since 1976.
38
Curr Probl Cancer, March/April 2006
37
Pharmacology from Dartmouth Medical School and her PhD in Pharmacology and Toxicology from the University of Louisville. She has conducted independent research and published in the fields of neurobehavioral pharmacology, gastroenterology, and molecular transport. She has also worked as an Associate Editor of the Journal of Pharmaceutical Sciences. Christopher Bole, MA, is a statistician in the Behavioral Medicine Unit in the Department of Radiation Oncology of the University of Rochester, James P. Wilmot Cancer Center. He completed his undergraduate degree in applied mathematics in 1989, and finished a graduate degree in mathematics and statistics in 1991. Subsequently, Mr. Bole held supervisory and senior analyst positions in the federal government and private industry. His work at the Cancer Center began in September of 2004, where he assists in the statistical training of new fellows, contributes original writing and to the editing of manuscripts, and provides computer programming support. Gary R. Morrow, PhD, MS, Professor of Radiation Oncology and Professor of Psychiatry, is the Associate Director for Cancer Control at the University of Rochester, James P. Wilmot Cancer Center, and Director of the URCC CCOP Research Base. He has been engaged in cancer control research at the University of Rochester since 1975, with a primary, sustained focus on side effect management and the methodology of clinical trials in cancer control. Dr. Morrow’s research has received continuous peer-reviewed research funding since 1976.
38
Curr Probl Cancer, March/April 2006